Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31

BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Pogue-Geile, Katherine L., Kim, Chungyeul, Jeong, Jong-Hyeon, Tanaka, Noriko, Bandos, Hanna, Gavin, Patrick G., Fumagalli, Debora, Goldstein, Lynn C., Sneige, Nour, Burandt, Eike, Taniyama, Yusuke, Bohn, Olga L., Lee, Ahwon, Kim, Seung-Il, Reilly, Megan L., Remillard, Matthew Y., Blackmon, Nicole L., Kim, Seong-Rim, Horne, Zachary D., Rastogi, Priya, Fehrenbacher, Louis, Romond, Edward H., Swain, Sandra M., Mamounas, Eleftherios P., Wickerham, D. Lawrence, Geyer, Charles E., Costantino, Joseph P., Wolmark, Norman, Paik, Soonmyung
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3848987/
https://ncbi.nlm.nih.gov/pubmed/24262440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt321
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki